Bayer Schering Pharma this week announced that it has scrapped
plans to introduce a double-dose version of its top-selling
multiple sclerosis (MS) drug Betaferon (interferon beta-1b) by the
end of the year following disappointing...
Merck Serono's new and improved version of its blockbuster multiple
sclerosis (MS) drug Rebif (interferon beta-1a) has been approved in
the EU, providing a little added protection to the company's MS
Merck Serono's revised formulation of its top seller Rebif
(interferon beta-1a) that offers improved tolerability for multiple
sclerosis sufferers has received a positive opinion from the
Committee for Medicinal Products for...
With a number of companies competing in the race to develop the
first oral treatment option for multiple sclerosis, UCB and Biogen
Idec's oral version of the infamous Tysabri has entered Phase II
A joint effort to develop a winning oral formulation for the
treatment of multiple sclerosis (MS) has taken another step towards
the finish line with initiation of Phase III trials for the novel
Novartis and Bayer Schering Pharma have come to an agreement
regarding the production of multiple sclerosis (MS) drug Betaseron
(interferon beta-1b), with Novartis planning to bring out its own
version in 2009 and Bayer paying around...